Sanofi

R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases

Retrieved on: 
Thursday, January 4, 2024
Janus, Atopic dermatitis, Receptor (biochemistry), Sanofi, Janus kinase, Hidradenitis suppurativa, Eosinophilic esophagitis, Autoimmunity, Inflammatory bowel disease, HS, Inflammation, Lupus, Blood, TLR, Therapy, Clinical trial, Asthma, JAK, Dupilumab, Roflumilast, Polyp (medicine), TPD, Webcast, Patient, Psoriasis, TYK2, STAT6, Skin, Sinusitis, Pharmaceutical industry

As part of its strategy, Kymera is unveiling two new programs that each have the potential to address multiple immune-mediated diseases, each with considerable market potential.

Key Points: 
  • As part of its strategy, Kymera is unveiling two new programs that each have the potential to address multiple immune-mediated diseases, each with considerable market potential.
  • Kymera will share its immunology strategy, including market insights, program updates, new preclinical data and development timelines, at its virtual R&D Day this morning.
  • In addition, at low oral doses, KT-621 demonstrated near full in vivo STAT6 degradation and was well-tolerated in multiple preclinical toxicity studies.
  • Kymera will host a webcast to discuss its emerging immunology pipeline from 10:00 a.m. – 12:00 p.m.

EQS-News: Evotec and Owkin enter an A.I.-powered strategic partnership to accelerate therapeutics pipeline in oncology and I&I

Retrieved on: 
Thursday, January 4, 2024
Science, Sanofi, Partnership, Drug discovery, Medicine, Risk, Biotechnology, IND, A.I, MOSAIC, EVO, ESG, Frankfurt Stock Exchange, Inflammation, MDAX, BMS, Investment, Communication, Patient, Fidelity, Intelligence, GV, BPI, Therapy, News, Neurology, Cryptocurrency

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Owkin, a French-American techbio company today announced an A.I.-powered integrated multi-target collaboration in oncology, immunology and inflammation (“I&I”).

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Owkin, a French-American techbio company today announced an A.I.-powered integrated multi-target collaboration in oncology, immunology and inflammation (“I&I”).
  • The collaboration brings together highly complementary platforms and expertise to accurately select targets, discover and develop new therapeutics.
  • Evotec will receive R&D funding from Owkin and is eligible to earn performance milestone payments and royalties on product sales.
  • Dr Matthias Evers, Chief Business Officer of Evotec, commented: “Owkin and Evotec both feel there is something special brewing by convergence between A.I.

FTC Files Amicus Brief Outlining Anticompetitive Harm Caused by Improper Orange Book Listings

Retrieved on: 
Wednesday, January 3, 2024
Federal Trade Commission, Policy, Sanofi, Orange Book, Food, Insulin glargine, FDA, Blog, Insulin, Diabetes, Orange, The Orange Book, News, Patent, FTC, Social media, Patient, Commission, District court, Pharmaceutical industry

Mylan alleges Sanofi monopolized the injectable insulin glargine market in part by abusing the FDA’s Orange Book regulatory process.

Key Points: 
  • Mylan alleges Sanofi monopolized the injectable insulin glargine market in part by abusing the FDA’s Orange Book regulatory process.
  • In September, the FTC issued a policy statement which warned that the agency would be scrutinizing the improper submission of patents for listing in the Orange Book.
  • The Commission’s statement warned that improper listings in the Orange Book may harm competition from cheaper generic alternatives and keep brand prices artificially high.
  • In November, the FTC sent letters to 10 drug manufacturers notifying them of more than 100 improperly listed Orange Book patents.

Statement Regarding the Termination of Sanofi’s Proposed Acquisition of Maze Therapeutics’ Pompe Disease Drug

Retrieved on: 
Wednesday, January 3, 2024
Federal Trade Commission, Sanofi, Acquisition, Blog, News, Competition, FTC, Maze, Social media, Patient

Following Sanofi’s decision to terminate its proposed acquisition of an exclusive license to Maze Therapeutics Inc.’s developmental drug to treat Pompe disease, the Federal Trade Commission moved to dismiss its case challenging the transaction.

Key Points: 
  • Following Sanofi’s decision to terminate its proposed acquisition of an exclusive license to Maze Therapeutics Inc.’s developmental drug to treat Pompe disease, the Federal Trade Commission moved to dismiss its case challenging the transaction.
  • The proposed deal would have allowed Sanofi to maintain its monopoly power by eliminating nascent competition, in turn reducing innovation for lifesaving, essential care.
  • The deal also would have enabled Sanofi to continue charging patients monopoly prices of over $750,000 for an annual course of treatment for its Pompe therapies.
  • For the latest news and resources, follow the FTC on social media, subscribe to press releases and read our blog.

Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 2, 2024
Conference, Sanofi, Therapy, Science, CATX

SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that Thijs Spoor, the Company’s Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Thursday, January 11, 2024, at 12 p.m. PT.

Key Points: 
  • SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that Thijs Spoor, the Company’s Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Thursday, January 11, 2024, at 12 p.m. PT.
  • Management will also participate at investor conferences alongside the J.P. Morgan Healthcare Conference in San Francisco.
  • 7th Annual BFC Global HealthCare BD & Investment Conference – Panel, “Great Science, Great Challenges: Partnership with the Big Pharma”
    Panelists: Executives from Novartis, Sanofi, Bayer, Johnson and Johnson Innovative Medicine, and AstraZeneca China
    Location: Hilton San Francisco - Union Square, Yosemite A (Ballroom Level)

Digital Transformation Summit India Announces The Top 100 Digital Leaders In India

Retrieved on: 
Monday, November 20, 2023
Petro, Vodafone Idea Ltd, SAP, Associate, Essar Group, Alkem Laboratories, Digital Solutions, USV, Information technology, Brookfield Renewable Partners, EPL, High Street Phoenix, Unichem Laboratories, Information, Shared services, Security, Reliance Power, CEAT (company), Region, Information officer, Laboratory, Great Eastern Shipping, HDFC Life, AVP, Union Bank, HDFC, HDFC Bank, DT, BNP Paribas, Digital, Johnson & Johnson, SBI, IndiaFirst Life Insurance Company, RPG Group, Digital transformation, Lead, Welspun Group, DPO, Fitting, Investment, Corporation, Infrastructure, Sanofi, Camlin Fine Sciences, Restaurant Brands, Thermo Fisher Scientific, CIO, VVF, Axis Bank, Bajaj Electricals, CISO, Union Bank of India, Wellington School, ICICI Prudential Life Insurance, Management

MUMBAI, INDIA, Nov 20, 2023 - (ACN Newswire) - The Digital Transformation Summit, India, a premier event at the forefront of technological innovation, is thrilled to unveil DT 100, a prestigious initiative that recognises the remarkable achievements of technology leaders in India.

Key Points: 
  • MUMBAI, INDIA, Nov 20, 2023 - (ACN Newswire) - The Digital Transformation Summit, India, a premier event at the forefront of technological innovation, is thrilled to unveil DT 100, a prestigious initiative that recognises the remarkable achievements of technology leaders in India.
  • The DT 100 felicitation will take place at the Digital Transformation Summit in Mumbai on the 6th of December.
  • As we eagerly anticipate the Digital Transformation Summit, we extend our heartfelt congratulations to the 100 leaders who are paving the way for a digitally empowered future.
  • For more information about the Digital Transformation Summit India and the DT 100, please visit https://digitransformationsummit.com/india/

Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint

Retrieved on: 
Thursday, December 21, 2023
Lung cancer, Sanofi, Docetaxel, Glycoprotein, Research, Spacecraft, Apoptosis, Progression-free survival, CEACAM5, Incidence, Cell adhesion, Cancer, Neoplasm, IDMC, Patient, PFS, NSCLC, Vaccine

CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival; tusamitamab ravtansine clinical development program will be discontinued

Key Points: 
  • CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival; tusamitamab ravtansine clinical development program will be discontinued
    PARIS, December 21, 2023.
  • Sanofi is discontinuing the global clinical development program of tusamitamab ravtansine.
  • An Independent Data Monitoring Committee (IDMC) found that tusamitamab ravtansine as a monotherapy did not meet its dual primary endpoint of progression-free survival (PFS) compared to docetaxel.
  • “Our team is grateful to the patients, families and healthcare professionals involved in the tusamitamab ravtansine development program.

Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa

Retrieved on: 
Friday, December 15, 2023
Risk, Movement, Death, Climate change, Infection, World Health Organization, Drought, Democratic republic, HAT, CHMP, Neglected tropical diseases, Cattle, Development, European, Disease, Human, African trypanosomiasis, Animal, SDC, Parasitic disease, Climate, Tropical medicine, Developing country, Tecnologia, Aggression, EMA, WHO, Project, International health, Patient, Sanofi, Partnership, Trypanosomiasis, Research, Trypanosoma brucei, Psychosis, Clinical trial, Somatic symptom disorder, Committee, Zoonosis, Pharmaceutical industry

Sanofi, DNDi and the HAT-r-ACC consortium announce the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive scientific opinion of Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense).

Key Points: 
  • Sanofi, DNDi and the HAT-r-ACC consortium announce the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive scientific opinion of Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense).
  • rhodesiense sleeping sickness, an acute and lethal form of this parasitic disease found in Eastern and Southern Africa.
  • Sleeping sickness, or human African trypanosomiasis (HAT), is usually fatal without treatment.
  • Both forms of sleeping sickness are transmitted by the bite of infected tsetse flies, which are found in 36 African countries.

Press Release: Availability of the Q4 2023 Memorandum for modelling purposes

Retrieved on: 
Friday, December 15, 2023
Sanofi

Paris, France – December 15, 2023.

Key Points: 
  • Paris, France – December 15, 2023.
  • Sanofi announced today that its Q4 2023 Memorandum for modelling purposes is available on the "Investors" page of the company's website:
    As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results.
  • This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count.
  • Sanofi's fourth-quarter 2023 results will be published on February 1, 2024.

BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs

Retrieved on: 
Monday, December 11, 2023
Dexmedetomidine, Cardiology, Agitation, FDA, Roche, Actelion, Reata Pharmaceuticals, GSK, Pfizer, IND, Adamas, Medicine, Physician, University, Mount Sinai School, Schizophrenia, Doctor of Philosophy, MEK, Journal of Clinical Pathology, Intermittent explosive disorder, GSK plc, New product development, Caregiver, EMA, Therapy, Patient, Intelligence, Development, Senior, DSM-IV codes, Bipolar disorder, Sanofi, Royal college, Acquisition, Prostate cancer, Clinical trial, Biogen, Pharmaceutical industry

NEW HAVEN, Conn., Dec. 11, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced a key executive promotion and a clinical advisor appointment as part of the Company’s strategic reprioritization focused on the advancement of its late-stage clinical programs and emerging pipeline candidates.

Key Points: 
  • Vincent J. O’Neill, M.D., Senior Vice President and Chief Research & Development Officer of OnkosXcel Therapeutics, has been promoted to Executive Vice President, Chief of Product Development and Medical Officer of BioXcel Therapeutics.
  • Additionally, Rajiv Patni, M.D., has been appointed to the newly created position of Strategic Clinical Advisor to the BioXcel Therapeutics Chief Executive Officer and Board of Directors.
  • Prior to joining BioXcel Therapeutics, Dr. O’Neill held senior leadership roles at several leading global pharmaceutical companies, including Sanofi, Genentech, and GlaxoSmithKline.
  • “I look forward to working with the BioXcel leadership team in continuing to address the unmet medical needs of patients and caregivers and advance the Company’s product-development goals.”